Abstract
At present the treatment of chronic hepatitis C virus infection is based on the combination of pegylated interferon (PEG-INF) and rivabirin (RBV) and basically attempts to eradicate the viral infection (sustained viral response). The pattern depends above all on the viral genotype, hence, patients with genotype 1, 4 and 5 require 48 weeks of treatment and high doses of RBV, while those with genotype 2 and 3 require 24 weeks of treatment and low doses of RBV. All patients with chronic C infection are possible candidates for antiviral therapy. However, given that the response to treatment is variable, that the treatment has secondary effects and supposes a high economic cost, it is recommendable in patients with hypertransaminasemia and moderate-severe chronic hepatitis in the histological study, as long as there are no counter-indications. This does not exclude other groups of patients who should be evaluated individually. In those patients with compensated hepatic cirrhosis, treatment can stabilise the disease and reduce the risk of complications appearing, although the rate of response is lower and some adverse effects are more frequent. In patients who have received previous antiviral treatment with standard interferon, alone...Continue Reading
References
Jan 1, 1986·Journal of Hepatology·F PiccininoG Giusti
Jun 1, 1996·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·M YanoK Okuda
Sep 1, 1996·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·V SorianoJ González-Lahoz
Jan 1, 1997·Journal of Hepatology·S Erlinger
Jan 1, 1997·Journal of Hepatology·B SotoE Lissen
Jan 6, 1999·JAMA : the Journal of the American Medical Association·J B WongS G Pauker
Sep 25, 1999·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Y BenhamouT Poynard
Jan 13, 2000·JAMA : the Journal of the American Medical Association·M S SulkowskiR D Moore
Aug 29, 2000·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·J F CadranelF Degos
Nov 18, 2000·Antimicrobial Agents and Chemotherapy·M SavèsC Leport
Dec 16, 2000·Lancet·G GreubA Telenti
Feb 15, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·I BicaD R Snydman
Feb 15, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·J H RexJ E Edwards
Feb 24, 2001·Lancet·A LafeuilladeS Chadapaud
Apr 12, 2001·Lancet·F Imbert-BismutUNKNOWN MULTIVIRC Group
May 12, 2001·Lancet·R Sandison
May 12, 2001·Lancet·V SorianoJ González-Lahoz
Jun 22, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·H K MongaB Yoffe
Aug 2, 2001·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·G Spinzi, G Minoli
Aug 21, 2001·Journal of Acquired Immune Deficiency Syndromes : JAIDS·M NúñezV Soriano
Oct 5, 2001·Lancet·M P MannsJ K Albrecht
Nov 16, 2001·AIDS Research and Human Retroviruses·L Martín-CarboneroJ González-Lahoz
Nov 28, 2001·The American Journal of Gastroenterology·G Garcia, E B Keeffe
Dec 4, 2001·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·V Di MartinoP Marcellin
Feb 9, 2002·AIDS·Mayte Pérez-OlmedaVincent Soriano
Mar 6, 2002·Journal of Viral Hepatitis·T PoynardUNKNOWN GERMED cyt04 group
Mar 29, 2002·AIDS·Vincent SorianoJürgen Rockstroh
Sep 26, 2002·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Xavier FornsJuan Rodés
Sep 27, 2002·The New England Journal of Medicine·Michael W FriedJian Yu
Citations
Nov 3, 2005·Nature Clinical Practice. Gastroenterology & Hepatology·Mark S Sulkowski
Jan 8, 2004·AIDS Research and Human Retroviruses·Mayte Pérez-OlmedaUNKNOWN HCV/HIV Spanish Study Group
Apr 20, 2004·AIDS·Vincent SorianoJurgen Rockstroh
Apr 13, 2004·AIDS·Jesús Santos, Rosario Palacios
Nov 1, 2005·Current Opinion in Infectious Diseases·Vincent SorianoMarina Nuñez
May 16, 2007·AIDS·Vincent SorianoJuergen Rockstroh
Dec 20, 2007·AIDS·Mark S SulkowskiDavid L Thomas
Feb 16, 2010·AIDS·Paula TumaVincent Soriano
Nov 1, 2007·Current Opinion in HIV and AIDS·Vincent SorianoPablo Barreiro
Nov 6, 2009·Antiviral Research·Vincent SorianoPablo Barreiro
Jan 24, 2004·Journal of Viral Hepatitis·V SorianoE Lissen
Jan 29, 2008·Journal of Viral Hepatitis·V de LédinghenV Soriano
Jan 22, 2010·Journal of Viral Hepatitis·F BlancoV Soriano
Jan 18, 2014·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Monica A KonermanMark S Sulkowski
Jan 27, 2015·Journal of Pharmaceutical and Biomedical Analysis·Tomokazu ItoTohru Yoshimura
Dec 20, 2005·Journal of Hepatology·Mark S Sulkowski
Dec 15, 2005·Journal of Hepatology·Vincent Soriano
Nov 22, 2005·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Jacques EmeritNicole Pavio
Oct 22, 2016·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Damien UlvelingUNKNOWN French ANRS HC EP 26 Genoscan Study Group
Sep 10, 2003·Journal of the International Association of Physicians in AIDS Care : JIAPAC·Daniel Fuster, Bonaventura Clotet
Mar 25, 2006·The Journal of Antimicrobial Chemotherapy·Vincent SorianoMarina Nuñez